Follow
Silvia Giordano
Silvia Giordano
Professor
Verified email at ircc.it
Title
Cited by
Cited by
Year
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti, P Michieli, M Galluzzo, M Mazzone, S Giordano, ...
Cancer cell 3 (4), 347-361, 2003
15912003
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family
C Ponzetto, A Bardelli, Z Zhen, F Maina, P dalla Zonca, S Giordano, ...
Cell 77 (2), 261-271, 1994
12291994
Drug development of MET inhibitors: targeting oncogene addiction and expedience
PM Comoglio, S Giordano, L Trusolino
Nature reviews Drug discovery 7 (6), 504-516, 2008
9692008
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
7122013
The dual roles of NRF2 in cancer
S Menegon, A Columbano, S Giordano
Trends in molecular medicine 22 (7), 578-593, 2016
6652016
Expression of the Met/HGF receptor in normal and neoplastic human tissues.
MF Di Renzo, RP Narsimhan, M Olivero, S Bretti, S Giordano, E Medico, ...
Oncogene 6 (11), 1997-2003, 1991
6431991
Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.
MF Di Renzo, M Olivero, A Giacomini, H Porte, E Chastre, L Mirossay, ...
Clinical cancer research: an official journal of the American Association …, 1995
6361995
Tyrosine kinase receptor indistinguishable from the c-met protein
S Giordano, C Ponzetto, MFD Renzo, CS Cooper, PM Comoglio
Nature 339 (6220), 155-156, 1989
5961989
From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage
S Giordano, A Petrelli
Current medicinal chemistry 15 (5), 422-432, 2008
5832008
The endophilin–CIN85–Cbl complex mediates ligand-dependent downregulation of c-Met
A Petrelli, GF Gilestro, S Lanzardo, PM Comoglio, N Migone, S Giordano
Nature 416 (6877), 187-190, 2002
5582002
The semaphorin 4D receptor controls invasive growth by coupling with Met
S Giordano, S Corso, P Conrotto, S Artigiani, G Gilestro, D Barberis, ...
Nature cell biology 4 (9), 720-724, 2002
5482002
Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene
C Ghigna, S Giordano, H Shen, F Benvenuto, F Castiglioni, PM Comoglio, ...
Molecular cell 20 (6), 881-890, 2005
4642005
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
MF Di Renzo, M Olivero, T Martone, A Maffe, P Maggiora, A De Stefani, ...
Oncogene 19 (12), 1547-1555, 2000
4312000
MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?
S Giordano, A Columbano
Hepatology 57 (2), 840-847, 2013
4232013
Negative receptor signalling
I Dikic, S Giordano
Current opinion in cell biology 15 (2), 128-135, 2003
4122003
Cancer therapy: can the challenge be MET?
S Corso, PM Comoglio, S Giordano
Trends in molecular medicine 11 (6), 284-292, 2005
3412005
Sema4D induces angiogenesis through Met recruitment by Plexin B1
P Conrotto, D Valdembri, S Corso, G Serini, L Tamagnone, PM Comoglio, ...
Blood 105 (11), 4321-4329, 2005
3232005
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages
JR Sierra, S Corso, L Caione, V Cepero, P Conrotto, A Cignetti, ...
The Journal of experimental medicine 205 (7), 1673-1685, 2008
3172008
Biosynthesis of the protein encoded by the c-met proto-oncogene.
S Giordano, MF Di Renzo, RP Narsimhan, CS Cooper, C Rosa, ...
Oncogene 4 (11), 1383-1388, 1989
3061989
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
JR Sierra, V Cepero, S Giordano
Molecular cancer 9, 1-13, 2010
2872010
The system can't perform the operation now. Try again later.
Articles 1–20